Equities Analysts Offer Predictions for iBio Q2 Earnings

iBio, Inc. (NYSE:IBIO) – Equities research analysts at Lifesci Capital issued their Q2 2026 earnings estimates for shares of iBio in a research note issued on Thursday, December 18th. Lifesci Capital analyst P. Dolezal expects that the company will earn ($0.12) per share for the quarter. The consensus estimate for iBio’s current full-year earnings is ($1.74) per share. Lifesci Capital also issued estimates for iBio’s Q3 2026 earnings at ($0.12) EPS, Q4 2026 earnings at ($0.12) EPS and FY2026 earnings at ($0.47) EPS.

Several other research analysts also recently issued reports on IBIO. Leerink Partners began coverage on iBio in a research report on Friday, October 17th. They set an “outperform” rating and a $2.00 price objective for the company. Oppenheimer reissued an “outperform” rating on shares of iBio in a research report on Wednesday, October 29th. Three research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $4.00.

iBio Stock Up 1.5%

Shares of NYSE IBIO opened at $2.01 on Monday. iBio has a 12-month low of $0.56 and a 12-month high of $6.89. The company has a market capitalization of $45.20 million, a PE ratio of -1.45 and a beta of 1.13. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.76 and a quick ratio of 1.76. The firm’s 50-day moving average is $1.40 and its two-hundred day moving average is $1.00.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Ameriprise Financial Inc. purchased a new stake in shares of iBio in the third quarter valued at $399,000. Citadel Advisors LLC acquired a new stake in iBio in the 3rd quarter worth about $109,000. Cubist Systematic Strategies LLC acquired a new stake in iBio in the 1st quarter worth about $224,000. Susquehanna International Group LLP purchased a new stake in iBio in the 3rd quarter valued at about $37,000. Finally, Boothbay Fund Management LLC increased its stake in shares of iBio by 10.9% during the 3rd quarter. Boothbay Fund Management LLC now owns 176,862 shares of the company’s stock valued at $146,000 after acquiring an additional 17,414 shares during the last quarter. Hedge funds and other institutional investors own 7.90% of the company’s stock.

iBio Company Profile

iBio, Inc (NYSE: IBIO) is a biotechnology company that develops and manufactures plant-based biologics, including vaccines and therapeutic proteins. Leveraging proprietary technology derived from Nicotiana benthamiana, a relative of tobacco, iBio applies a molecular farming approach to produce complex proteins more rapidly and with greater scalability than traditional cell-culture methods. The company’s core expertise lies in its ability to design, express and purify recombinant proteins for both research and commercial applications.

Central to iBio’s operations is the iBio CDM™ (cGMP-Direct Manufacture) platform, an integrated system that enables end-to-end development and production of biologics.